Pharmafile Logo

Lumena Pharmaceuticals

- PMLiVE

FDA sets out framework for rare childhood diseases

Wants to encourage more trial use of biomarkers and speedier approval timelines

- PMLiVE

AbbVie raises Shire bid to £30bn

Latest offer is company’s fourth attempt at takeover

- PMLiVE

The moving parts of orphan drug development

Tackling rare diseases requires high levels of cooperation, regulatory support and a determination to succeed

- PMLiVE

FDA gives early green light to Spectrum’s lymphoma drug

Beleodaq approved to treat rare cancer

Shire Basingstoke

Shire spells out why AbbVie takeover is a bad idea

Talks up its growth prospects as an independent company

Shire Basingstoke

Shire turns down takeover offer from AbbVie

Marks third time UK pharma company has turned down AbbVie's advances

- PMLiVE

Valeant takeover bid for Allergan turns hostile

Canadian firm goes directly to shareholders with offer

- PMLiVE

Otsuka launches European ADPKD forum

Aims to lead awareness raising plans for rare genetic condition

- PMLiVE

EC approves Janssen rare blood disorder drug

Sylvant available to treat multicentric Castleman's disease

Shire Basingstoke

Shire boosts rare disease portfolio with $260m Lumena deal

Acquisition of US company will bring two mid-stage candidates for rare liver diseases

Biomarin

EC approves Biomarin rare genetic disorder drug

Vimizim now available to treat Morquio A syndrome

- PMLiVE

FDA approves Janssen drug for rare Castleman’s disease

Sylvant approved to treat lymphoma-like condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links